Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06749418 · ClinicalTrials.gov registry record · Early Phase 1
Vascular Effects of High-Salt After Preeclampsia
A Early Phase 1 study of Preeclampsia and Preeclampsia Postpartum, sponsored by Anna Stanhewicz, PhD.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06749418 is a Early Phase 1 study of Preeclampsia and Preeclampsia Postpartum that is actively recruiting participants, run by Anna Stanhewicz, PhD. The registered enrollment target is 40 participants, below the 1,281-participant average among 39 other Preeclampsia trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06749418, a Early Phase 1 study of Preeclampsia and Preeclampsia Postpartum, is actively recruiting participants, sponsored by Anna Stanhewicz, PhD.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. Importantly, women who had preeclampsia have an exaggerated vascular responsiveness to hypertensive stimuli, such as high-salt intake, compared to women who had a healthy pregnancy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. While the association between a history of preeclampsia and vascular dysfunction leading to elevated CVD risk is well known, the mechanisms underlying this dysfunction remains unclear. The purpose of this study is to examine the role of vascular mineralocorticoid receptor, the terminal receptor in the angiotensin system that contributes to blood pressure regulation, in mediating exaggerated microvascular endothelial dysfunction before and after a high-salt stimulus. This will help us better understand the mechanisms of microvascular dysfunction these women, and how inhibition of these receptors may improve microvascular function. In this study, we use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a nickel-sized area of the skin.
Conditions Studied
Interventions
- DRUG Eplerenone
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-01-02 |
| Est. Completion | 2027-11-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06749418
The ClinicalTrials.gov registry entry for NCT06749418 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,281-participant average among 39 other Preeclampsia trials with a reported enrollment target (97% lower). The listed sponsor is Anna Stanhewicz, PhD, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Preeclampsia appearing as the primary indexed condition, and to 1 intervention - of which Eplerenone is the first listed.
NCT06749418 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT06749418 about?
NCT06749418 is a clinical study titled "Vascular Effects of High-Salt After Preeclampsia". Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. Importantly, women who had preeclampsia have an exaggerated vascular responsiveness to hypertensive stimuli, such as high-salt intake, compa...
What is the current status of trial NCT06749418?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2025-01-02. Estimated completion is 2027-11-15.
What conditions does trial NCT06749418 study?
This clinical trial studies the following conditions: Preeclampsia, Preeclampsia Postpartum.
What interventions are being tested in trial NCT06749418?
The interventions under investigation include: Eplerenone (DRUG).
Who is sponsoring clinical trial NCT06749418?
This trial is sponsored by Anna Stanhewicz, PhD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06749418 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Daily Aspirin Treatment After Preeclampsia
RECRUITING · Early Phase 1
-
Prenatal Aspirin and Postpartum Vascular Function
RECRUITING · Early Phase 1
-
Predictors of Aspirin Failure in Preeclampsia Prevention
RECRUITING · Early Phase 1
-
MR and Inflammation After Preeclampsia
ACTIVE NOT RECRUITING · Early Phase 1
-
Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)
COMPLETED · Early Phase 1
-
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.